[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337443-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337443-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cuproptosis-related-genes-predict-prognosis-and-trastuzumab-therapeutic-response-in-her2-positive-breast-cancer","Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer","","Cuproptosis is a newly recognized programmed cell death driven by copper-mediated mitochondrial lipoylation and destabilization of iron-sulfur proteins. Roles of cuproptosis-related genes (CRGs) in HER2-positive breast cancer were unclear, so a prognostic prediction model was built using TCGA and therapy-resistant dysregulated genes from GEO. Functional analyses included KEGG/GO and GSEA, with immune assessment via CIBERSORT and TIDE. A four-CRG signature linked higher CRGs risk to shorter OS, and DLAT downregulation associated with better survival and trastuzumab sensitivity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cuproptosis-related-genes-predict-prognosis-and-trastuzumab-therapeutic-response-in-her2-positive-breast-cancer/337443/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cuproptosis-related-genes-predict-prognosis-and-trastuzumab-therapeutic-response-in-her2-positive-breast-cancer/337443.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was the prognostic prediction model constructed in the study?","Question",{"text":63,"@type":64},"The study used the TCGA database to build a prognostic prediction model for HER2-positive breast cancer patients, and used the GEO dataset to analyze dysregulated genes related to resistance to HER2-targeted therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which gene was identified as a key factor, and what was its association with outcomes?",{"text":68,"@type":64},"DLAT was downregulated and correlated with better survival in HER2-positive breast cancer, and it was identified as an independent prognostic factor.",{"name":70,"@type":61,"acceptedAnswer":71},"How does DLAT affect trastuzumab therapeutic response?",{"text":72,"@type":64},"Higher DLAT expression was associated with resistance to HER2-targeted therapy. Knocking down DLAT with siRNA increased the sensitivity of breast cancer to trastuzumab.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337443,1790222707,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nCuproptosis‑related genes predict prognosis and trastuzumab therapeutic response in HER2‑positive breast cancer  \nRui Sha1,8, Xinrui Dong2,8, Shanshan Yan3,8, Huijuan Dai4, Aijun Sun5*, Liuxia You6* & Zongjin Guo7*  \nBreast cancer is the most common diagnosed cancer, the HER2‑positive subtype account for 15% of all breast cancer. HER2‑targeted therapy is the mainstay treatment for HER2‑positive breast cancer. Cuproptosis is a novel form of programmed cell death, and is caused by mitochondrial lipoylation and destabilization of iron‑sulfur proteins triggered by copper, which was considered as a key player in various biological processes. However, the roles of cuproptosis‑related genes in HER2‑positive breast cancer remain largely unknown. In the present study, we constructed a prognostic prediction model of HER2‑positive breast cancer patients using TCGA database. Dysregulated genes for cells resistant to HER2‑targeted therapy were analyzed in the GEO dataset. KEGG pathway, GO enrichment and GSEA was performed respectively. The immune landscape of DLAT was analyzed by CIBERSORT algorithm and TIDE algorithm. HER2‑positive breast cancer patients with high CRGs risk score showed shorter  \nOS. DLAT was downregulated and correlated with better survival of HER2‑positive breast cancer patients (HR = 3.30, p = 0.022) . High expressed DLAT was associated with resistant to HER2‑targeted therapy. Knocking down DLAT with siRNA increased sensitivity of breast cancer to trastuzumab. KEGG pathway and GO enrichment of DEGs indicated that DLAT participates in various pathways correlated with organelle fission, chromosome segregation, nuclear division, hormone‑mediated signaling pathway, regulation of intracellular estrogen receptor signaling pathway, condensed chromosome and PPAR signaling pathway. There was a negative correlation between TIDE and DLAT expression (r = − 0.292, p \u003C 0.001), which means high DLAT expression is an indicator of sensitivity to immunotherapy. In conclusion, our study constructed a four CRGs signature prognostic prediction model and identified DLAT as an independent prognostic factor and associated with resistant to HER2‑targeted therapy for HER2‑positive breast cancer patients.  \nBreast cancer (BC) has become the most frequently diagnosed cancer, and it is also the leading cause of cancerrelated death in women worldwide1,2. BC can be divided into four conventional subtypes, Luminal A, Luminal B, human epidermal growth factor 2 (HER2) positive and triple negative breast cancer (TNBC)3. Endocrine therapy is used for individuals with hormone receptor positive disease, chemotherapy is the primary treatment option for TNBC, and HER2-targeted therapy is utilized for patients whose tumors overexpress HER24,5.  \nAbout 15% of patients developed HER2-positive BC, which was characterized by a high recurrence rates, aggressive phenotype, and poor survival outcomes6,7. The monoclonal antibody trastuzumab significantly  \n1Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital ofWannan Medical College), 2 Zheshan West Road, Wuhu 241001, Anhui, China. 2Department of Breast Surgery, The First Affiliated Hospital With Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, China. 3Center for Medical Ultrasound, Suzhou Municipal Hospital, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou 215000, Jiangsu, China. 4Renji Hospital, School of Medicine, Shanghai Jiaotong University, 1630 Dongfang Road, Shanghai 200127, China. 5Department of Thyroid and Breast Oncological Surgery, Xuzhou Medical College Affiliated Huaian Hospital, 62 Huaihai South Road, Huaian 223001, Jiangsu, China. 6Department of Clinical Laboratory, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian, China. 7Department of Interventional Radiology, The University of HongKon","cbCainWKibhdiFHl","https://ap.wps.com/l/cbCainWKibhdiFHl","pdf",6448233,15,"English","# Background\n## HER2-positive breast cancer and cuproptosis\n# Study Design and Methods\n## Data sources (TCGA, GEO)\n## Pathway and enrichment analyses\n## Immune landscape and TIDE assessment\n# Results\n## CRG risk score and overall survival\n## DLAT expression and trastuzumab resistance\n## Functional pathway involvement\n# Conclusion","[{\"question\":\"How was the prognostic prediction model constructed in the study?\",\"answer\":\"The study used the TCGA database to build a prognostic prediction model for HER2-positive breast cancer patients, and used the GEO dataset to analyze dysregulated genes related to resistance to HER2-targeted therapy.\"},{\"question\":\"Which gene was identified as a key factor, and what was its association with outcomes?\",\"answer\":\"DLAT was downregulated and correlated with better survival in HER2-positive breast cancer, and it was identified as an independent prognostic factor.\"},{\"question\":\"How does DLAT affect trastuzumab therapeutic response?\",\"answer\":\"Higher DLAT expression was associated with resistance to HER2-targeted therapy. Knocking down DLAT with siRNA increased the sensitivity of breast cancer to trastuzumab.\"}]","Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer | PDF",1790019169,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d574478afb68bcd5d5cda1f248b88132.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84980937706f440fb82e0ae62c14be46.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/059cf10328dd3465385f95569e76aaca.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ae05809e6b2bcc3989abf9de89c4e41.webp",980,1287]